Theraclion SA announced a private placement of minimum 19,064,124 shares with warrants attached (the "ABSAs") for gross proceeds of ?11 million and maximum 21,923,742 ABSAs for a gross proceeds of ?12.7 million on May 24, 2023. The transaction will include participation from returning investor, Furui Medical Science Company Luxembourg S.à r.l. for ?7 million which included ?6 million for capital increase and ?1 million for warrants. The six new shares will give the right to subscribe to one new share at a price of ?0.577.

The transaction is expected to close on June 15, 2023. The transaction has been approved by the board of directors of the company.